Role of Positron Emission Tomography/Computed Tomography in Bone Malignancies

被引：13
作者：
Peller, Patrick J. [1 ,2 ]
机构：
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Radiol, Rochester, MN 55905 USA
来源：
RADIOLOGIC CLINICS OF NORTH AMERICA | 2013年 / 51卷 / 05期
关键词：
Fluorodeoxyglucose; Positron emission tomography; PET/CT; Osteosarcoma; Bony metastasis; Multiple myeloma; DIAGNOSED MULTIPLE-MYELOMA; METASTATIC BREAST-CANCER; EWING SARCOMA FAMILY; FDG-PET; FOLLOW-UP; CHEMOTHERAPY RESPONSE; OSTEOGENIC-SARCOMA; IMAGING TECHNIQUES; PROGNOSTIC-FACTORS; THERAPY RESPONSE;
D O I：
10.1016/j.rcl.2013.05.005
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
This article presents an overview of positron emission tomography combined with computed tomography (PET/CT) imaging of bone tumors for the practicing radiologist. The clinical roles and utility of F-18-labeled fluorodeoxyglucose PET/CT in patients with primary bone tumors, osseous metastases, and multiple myeloma are reviewed. The clinical and research data supporting the utility of PET/CT in the evaluation of skeletal malignancies continues to grow.
引用
收藏
页码：845 / +
页数：21
相关论文
共 113 条
[1]   The role of nuclear medicine in primary bone and soft tissue tumors [J].
AbdelDayem, HM .
SEMINARS IN NUCLEAR MEDICINE, 1997, 27 (04) :355-363
[2]  
American Joint Committee on Cancer, 2010, AJCC CANC STAGING MA, P281
[3]   Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321 [J].
Barlogie, B ;
Kyle, RA ;
Anderson, KC ;
Greipp, PR ;
Lazarus, HM ;
Hurd, DD ;
McCoy, J ;
Dakhil, SR ;
Lanier, KS ;
Chapman, RA ;
Cromer, JN ;
Salmon, SE ;
Durie, B ;
Crowley, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :929-936
[4]   F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma [J].
Bartel, Twyla B. ;
Haessler, Jeff ;
Brown, Tracy L. Y. ;
Shaughnessy, John D., Jr. ;
van Rhee, Frits ;
Anaissie, Elias ;
Alpe, Terri ;
Angtuaco, Edgardo ;
Walker, Ronald ;
Epstein, Joshua ;
Crowley, John ;
Barlogie, Bart .
BLOOD, 2009, 114 (10) :2068-2076
[5]   The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis [J].
Bastiaannet, E ;
Groen, H ;
Jager, PL ;
Cobben, DCP ;
van der Graaf, WTA ;
Vaalburg, W ;
Hoekstra, HJ .
CANCER TREATMENT REVIEWS, 2004, 30 (01) :83-101
[6]  
Bertoni F., 2002, WHO CLASSIFICATION T, P247
[7]   Use of FDG PET in Staging, Restaging, and Assessment of Therapy Response in Ewing Sarcoma [J].
Bestic, Joseph M. ;
Peterson, Jeffrey J. ;
Bancroft, Laura W. .
RADIOGRAPHICS, 2009, 29 (05) :1487-U331
[8]  
Beyer T, 2002, Q J NUCL MED, V46, P24
[9]   Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas [J].
Bredella, MA ;
Caputo, GR ;
Steinbach, LS .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (05) :1145-1150
[10]   FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients [J].
Brenner, W ;
Conrad, EU ;
Eary, JF .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (02) :189-195
12345678910